Krystal Biotech Inc (KRYS) — Cash Flow-to-Debt Ratio
Krystal Biotech Inc (KRYS) has a Cash Flow-to-Debt Ratio of 0.67x as of March 2026, meaning its operating cash flow of $80.38 Million could theoretically repay 1% of its total liabilities ($120.24 Million) in one year. Explore Krystal Biotech Inc (KRYS) long-term investment share to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Krystal Biotech Inc Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Krystal Biotech Inc across 10 annual periods. Also explore Krystal Biotech Inc (KRYS) total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Krystal Biotech Inc (2016–2025)
Year-by-year debt coverage analysis for Krystal Biotech Inc. For market capitalisation and broader financial context, see how much is Krystal Biotech Inc worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 1.76x | $200.87 Million | $114.23 Million | ▲ +55.9% |
| 2024 | 1.13x | $123.42 Million | $109.46 Million | ▲ +150.4% |
| 2023 | -2.24x | $-88.80 Million | $39.71 Million | ▲ +19.5% |
| 2022 | -2.78x | $-100.57 Million | $36.22 Million | ▼ -89.5% |
| 2021 | -1.47x | $-47.94 Million | $32.72 Million | ▼ -5.4% |
| 2020 | -1.39x | $-26.08 Million | $18.76 Million | ▲ +54.6% |
| 2019 | -3.06x | $-18.71 Million | $6.11 Million | ▲ +6.3% |
| 2018 | -3.27x | $-9.45 Million | $2.89 Million | ▲ +46.2% |
| 2017 | -6.08x | $-3.89 Million | $640.00K | ▼ -777.6% |
| 2016 | -0.69x | $-1.31 Million | $1.89 Million | — |